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Background: Achromobacter xylosoxidans infection may cause conspicuous chronic pulmonary inflammation in cystic fibrosis (CF) patients
similar to Pseudomonas aeruginosa and the Burkholderia cepacia complex (Bcc). Evolution in lung function was compared in chronically
infected patients. Cytokine concentrations in CF patients with and without chronic infection were compared to healthy controls.
Methods: Cytokines in serum and sputum were measured using multiplex bead based immunoassay.
Results: Sixty CF patients, 11 with A. xylosoxidans, 11 with Bcc, 21 with P. aeruginosa and 17 non-infected CF patients were compared to 11 healthy
controls. A. xylosoxidans patients were younger, but had a FEV1 decline similar to P. aeruginosa patients. Bcc patients had the steepest decline in
FEV1.
Serum levels of G-CSF, IL-6 and TNF-α were significantly higher in CF patients compared to healthy controls. Chronically infected CF
patients had significantly higher serum levels of IFN-γ and IL-6 compared to non-infected CF patients. Bcc patients had significantly lower serum
G-CSF and A. xylosoxidans patients had significantly higher sputum TNF-α compared to the other groups of chronically infected patients.
Conclusion: A. xylosoxidans can cause a level of inflammation similar to P. aeruginosa in chronically infected CF patients. A. xylosoxidans is a
clinically important pathogen in CF and should be treated accordingly.
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Recurrent and ultimately chronic pulmonary infection is a
predominant cause of increased morbidity and mortality in cystic
fibrosis (CF) patients [1–3]. Up to 80% of adult CF patients
suffer from chronic, pulmonary infection with Pseudomonas
aeruginosa, but an increasing number of other Gram-negative☆ Preliminary data have been presented at: the 6th annual Cytokines and
Inflammation Congress in Orlando, Florida, January 28–29, 2008; at the 8th
International Congress on Pediatric Pulmonology in Nice, France, March 29–
31, 2008; at the American Thoracic Society Annual Conference in Toronto,
Canada, May 16–21, 2008 and at the 22nd North American CF Conference in
Orlando, Florida, October 23–25, 2008.
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1569-1993/$ - see front matter © 2009 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2009.10.005microorganisms are capable of causing chronic infections in CF
patients [4,5].
In CF, the inflammatory response to pulmonary infections is
exaggerated [6,7]. Increased levels of inflammatory cytokines
have been found in sputum [8], BAL-fluid [9–11] and Exhaled
Breath Condensate (EBC) [12] not only in chronically infected
patients but even in CF infants without established infections
[10,13,14]. Levels of cytokines in BAL-fluid are increased in
individuals with airway infection compared to individuals
without infection [7,9,15].
Inflammation caused by P. aeruginosa has been described
through the studies of mouse models of chronic infection; by
measurements of cytokines in BAL-fluid, sputum and serum
[8,16]; by stimulation of peripheral blood mononuclear cells
(PBMC) from patients with chronic P. aeruginosa infection [17]
andmeasurements of specific antibody levels [18]. The increased
morbidity and mortality in CF patients with this infection is welld by Elsevier B.V. All rights reserved.
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to a poor prognosis in these patients [20].
The Burkholderia cepacia complex (Bcc) affects 3–4% of CF
patients [4,21–26]. The prevalence varies greatly in individual
centres since some Bcc genomovars have shown a high ability to
cause cross infections within centres [27–29]. Bcc infection is
feared due to the ability to cross infect [29,30] and to cause the
cepacia syndrome — characterized by a sudden decline in
clinical status and a high mortality [26,30–32]. B. cepacia
lipopolysaccharide (LPS) can strongly stimulate the inflamma-
tory response [33], but a study revealed no difference in levels of
inflammatory markers between CF patients with B. cepacia and
patients with chronic P. aeruginosa infection [34].
Another new cause of chronic pulmonary infection is
Achromobacter xylosoxidans found in around 7% of the CF
population [35]. The clinical significance of this infection is still
not clearly established. A few studies have shown a negative
impact on CF pulmonary disease, especially in patients with a
rapid increase in specific antibodies [36], whereas other studies
failed to demonstrate any correlation [37–39]. A recent study has
shown an overrepresentation of A. xylosoxidans infected patients
in the group of CF patients in need of lung transplantation
compared to prevalence of A. xylosoxidans in the general CF
population (presented as abstract 359 by Brown et al. at the 22nd
NACFC in 2008, Orlando, Florida).
The aim of the present study was to evaluate the inflammatory
response to A. xylosoxidans by comparing concentrations of
inflammatory markers in serum, EBC and sputum from patients
chronically infected withP. aeruginosa, Bcc andA. xylosoxidans,
respectively, CF patients without chronic, pulmonary infections
caused by Gram-negative microorganisms and healthy controls.
2. Methods
2.1. Study design
Cross sectional and retrospective study of patients followed
at the Copenhagen CF centre. Patients were invited to par-
ticipate at outpatient visits and samples for cytokine measure-
ments were collected during a 2 year period.
2.2. Treatment strategy at Copenhagen CF centre
Patients are seen on a regular, monthly basis. At all visits, the
clinical status of the patients is assessed by weight, height and
lung function parameters, forced vital capacity (FVC) and
forced expiratory volume in 1 s (FEV1) (Masterscreen Pneumo,
Jaeger) are obtained according to the ATS guidelines [40], using
reference values from Polgar [41]. Lower respiratory tract
secretions for microbiological investigation are obtained by
coughing or by endo-laryngeal suctioning. Specific, precipitat-
ing antibodies are obtained at least once every year, and chronic
infection is defined as 6 consecutive positive sputum samples
and/or elevated levels of specific, precipitating antibodies [20].
The specificity of the antibody response is determined by
absorption experiments [20]. CF patients with chronic, Gram-
negative, pulmonary infections are treated with 3-monthly elec-tive courses of 2 weeks of i.v. antibiotics and with continuous
inhaled antibiotics.
2.3. Patients
All patients treated at CF centre Copenhagen were eligible for
the study. Patients were characterized as non-infected or
chronically infected with A. xylosoxidans, Bcc or P. aeruginosa.
Preferably, subjects without chronic infections were chosen
among patients ≥15 years securing their own agreement to give
informed consent and better age-match to chronically infected
patients. Patients chronically infected with more than one Gram-
negative microorganism were not included in analyses to avoid
contributing inflammatory stimulation from more than one
infectious agent. All patients had a confirmed diagnosis of CF
based on abnormal sweat electrolytes, characteristic clinical
features and genotype.
Healthy controls were recruited from the staff at the centre.
2.4. Lung function parameters and specific antibodies
Highest value of FEV1 and highest level of specific antibodies
were collected retrospectively for each year of observation,
starting the year prior to development of chronic infection, up to
12 years after development of chronic infection. Slope of decline
of FEV1 was calculated as change in % of predicted/year,
including all years of chronic infection.
Highest value of FEV1 in the year prior to development of
chronic infection in the A. xylosoxidans group was compared to
a group of controls without chronic, pulmonary infections. Two
CF controls, matched on age (±1 year) and gender, were found
for each A. xylosoxidans infected patient.
2.5. Biofilms
Gram-stained smears of sputum were searched for biofilms
of Bcc and A. xylosoxidans by microscopy as previously
reported in relation to chronic infectionwithmucoidP. aeruginosa
[42].
2.6. Samples for cytokine measurements
Samples were taken at least 2 months after a course of i.v.
antibiotics to avoid any antibiotic suppression of inflammation
[43–45]. The following samples were collected from each
participant: serum sample, EBC and, if possible, sputum
sample. Age, duration of chronic infection, FEV1 and level of
specific antibodies, were noted at the time of the sample.
Serum: blood samples were allowed to clot. Serum was
collected after centrifugation for 10 min at 3000 rpm.
Exhaled Breath Condensate: samples were collected using
Ecoscreen® (Jäeger, Hoechberg, Germany). Patients were
allowed to breathe normally for 15 min, wearing a nose-clip.
After collection, EBC was frozen immediately.
Sputum: Fresh, spontaneously expectorated sputum samples
were frozen and stored at −80 °C until preparation. Samples
were ultra-centrifuged for 4 h at 38,000 rpm. Non-infected CF
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samples from the chronically infected groups were analyzed.
All samples were stored at −80 °C prior to analysis.
2.7. Cytokines
Cytokines in serum, EBC and sputum were measured by a
multiplexed flow cytometric assay using a human cytokine
LINCOplex kit (MPXHCYTO-60 K, Linco Research, St.
Charles, MO, USA) and a human high sensitivity LINCOplex
kit (HSCYTO-60SK, Linco Research, St. Charles, MO, USA)
on a Luminex® 100TM system (Ramcon, Birkerød, Denmark).
In serum and sputum, measurements of G-CSF, IFN-γ, TNF-α,
IL-6, IL-8 and IL-10 were done. In EBCmeasurements of IFN-γ,
TNF-α, IL-1β, IL-6 and IL-10 were done. Analysis was done
according to the instructions of the manufacturer. Samples were
measured in duplicates. The range of the standard curves for all
cytokines measured was 3.2–10.000 pg/ml. To minimize varia-
tion, the same person ran each entire set of samples on the same
day. Based on the standard curves, the coefficient of variation
(CV) was calculated and did not exceed 20%.
2.8. Microbiology
Bacterial resistance against commonly used antibiotics was
tested in isolates from included subjects. A strain was defined as
multiresistant if simultaneous resistances to at least 3 different
groups of antibiotics were found (aminoglycosides, 3rd gener-
ation cephalosporins, colistin, aztreonam, meropenem, cipro-
floxacin, tetracycline, chlorampenicol, sulfamethoxazole with
trimethoprim and penicillin with β-lactamase inhibitor).
2.9. Statistics
Data and measurements with a normal distribution were
compared using one-way ANOVA. More than two groups of
data that were not normally distributed were compared using
Kruskal–Wallis test. Mann–Whitney Rank Sum test was used
for comparison of two groups of data without normal dis-
tribution. Correlation of duration of chronic infection to level ofTable 1
Demographic data expressed as numbers (number of patients in groups, genotype an
FEV1, chronic infection duration).
CF patients according to infectious st
No chronic infection A. xylosoxidan
Number (males) 17 (6) 11 (6)
Age (years) 17.8 (8.6–25.7) ⁎ 20.4 (16.1–26
Number of specific, precipitating antibodies – 19 (1–43)
FEV1% predicted 83.2 (51.8–97.4) ⁎ 83 (30.9–10
Chronic infection duration (years) – 4.6 (2.8–10.4
ΔF508 homozygous 10 (7 F508/other) 7 (4 F508/o
CF related diabetes 4/17 2/11
All data were assessed at the time of sample collection. All groups were compared
showed a significant result, the groups were compared to each other, two at a time,
⁎ pb0.01 using Mann–Whitney test.FEV1 and specific antibodies, respectively, was done in the
individual groups of chronically infected patients using
Spearman's correlation. Level of significance was defined as
0.05 (two-tailed).
3. Results
Sixty-seven CF patients and 11 healthy controls were
included. Fifty CF patients had chronic pulmonary infections:
14 patients with A. xylosoxidans, 21 with P. aeruginosa, 13 with
B. multivorans and 2 with B. cepacia. The last 15 patients were
grouped together as the Bcc group. Of the chronically infected
CF patients, 3 patients in the A. xylosoxidans group and 4
patients in the Bcc group were co-infected with other Gram-
negative microorganisms. Six patients were co-infected with P.
aeruginosa (2 in the A. xylosoxidans group, 4 in the Bcc group)
and one patient initially having chronicA. xylosoxidans infection
developed chronic B. multivorans infection and continued to
have sputum cultures positive for both microorganisms. All 7
patients with co-infections were excluded from further analyses,
leaving 11 patients in the A. xylosoxidans group and 11 patients
in the Bcc group. Seventeen CF patients did not have chronic,
Gram-negative, pulmonary infection. Demographic data are
shown in Table 1. CF patients without chronic infections were
younger compared to the P. aeruginosa group, the Bcc group
and the healthy controls, but not when compared to the A.
xylosoxidans group. Non-infected CF patients had the highest
FEV1 when comparing all groups of CF patients (Table 1).
Within the group of chronically infected patients, the A.
xylosoxidans group was younger (pb0.003). The P. aeruginosa
group had the longest duration of chronic infection (pb0.002)
(Table 1).
3.1. Biofilms
Seven of eight and 6/6 of the CF patients with chronic A.
xylosoxidans and Bcc, respectively, had detectable biofilm-like
clusters of Gram-negative rods surrounded by a matrix in sputum
(Fig. 1). The remaining patients in these two groups either har-
boured other Gram-negative rods or only produced pharyngeald occurrence of CF related diabetes) or median (range) (age, specific antibodies,
atus Healthy controls p-value
s P. aeruginosa Bcc
21 (13) 11 (5) 11 (2) n.s.
.9) ⁎ 29.5 (13.7–43.4) 28.5 (19.2–41.6) 25.7 (21.1–39.1) pb0.001
23 (3–48) 15 (5–30) – n.s.
4.2) 59.5 (26.5–109.6) 66.5 (30.9–99.3) – pb0.02
) 16.9 (0.1–30.7) ⁎ 8.7 (2–12.8) – pb0.002
ther) 15 (6 F508/other) 9 (2 F508/other) – n.s.
5/21 2/11 0/11 n.s.
using Kruskal–Wallis test (p-values given in table). When Kruskal–Wallis test
using Mann–Whitney test.
Fig. 1. A. xylosoxidans biofilm in CF sputum. Biofilm found in sputum from a CF patient chronically infected with A. xylosoxidans for 7.5 years.
Fig. 2. Change in FEV1, % predicted/year, up to 12 years of chronic infection.
Figure shows individual values, mean and 95% confidence interval: A.
xylosoxidans: −1.9 (−0.2 to −3.6), Bcc: −3.6 (−4.9 to −2.2) and P. aeruginosa:
−1.1 (−2.2 to +0.05) (pb0.005).
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patients with chronic mucoid P. aeruginosa lung infections have
previously been shown to have biofilm in sputum [42]. Compared
to P. aeruginosa biofilms in sputum, the biofilms of A.
xylosoxidans and Bcc looked similar with a dark, condensed
appearance where the bacterial cells were located very close to
each other in contrast to the biofilms of mucoid P. aeruginosa
where the abundant light alginate matrix leads to separation of the
individual bacterial cells.
3.2. Specific antibodies and change in lung function
In all groups of chronically infected patients, a significant
positive correlation between duration of chronic infection and
levels of specific antibodies was found (Spearman's rho=0.587,
pb0.001).
When comparing level of FEV1 in the year prior to
development of chronic infection in the 3 groups of chronically
infected patients, no difference was found. Patients in the A.
xylosoxidans, Bcc and P. aeruginosa groups had a median
(range) FEV1, % of predicted, of 94.7 (55.7 to 118.9), 103.5
(54.9 to 110.8) and 83.5 (51.7 to 116.5), respectively (n.s.). The
A. xylosoxidans group was compared to a group of controls
matched on age and gender. In the year prior to development of
chronic infection in the A. xylosoxidans group, the CF controls
without chronic infections had a median (range) FEV1, % of
predicted, of 94.4 (74.2–126.4) (n.s.).
In all groups of chronically infected patients, a small, but
significant negative correlation between duration of chronic
infection and levels of FEV1 decline, % of predicted/year was
found (Spearman's rho=−0.287, pb0.001). TheA. xylosoxidans,
Bcc and P. aeruginosa group had a median (range) change in
FEV1 of−1.7 (−7.5 to +2.3),−3.7 (−7.6 to−0.2) and−0.9 (−9.1to +2.1), respectively. The Bcc group had a greater lung function
decline compared to the other groups (pb0.005) (Fig. 2).
3.3. Serum levels of cytokines
CF patients had higher concentrations of TNFα in serum
compared to healthy controls (Fig. 3) (pb0.003). No difference
was found when comparing CF patients with and without
chronic, Gram-negative infections.
Concentrations of G-CSF were highest in the A. xylosox-
idans and the P. aeruginosa groups compared to all other
groups (Fig. 4) (pb0.001). Within the groups of chronically
infected patients, the Bcc group had lower levels of G-CSF
compared to the A. xylosoxidans group (pb0.02) and to the P.
aeruginosa group (pb0.01).
Fig. 3. Level of TNF-α (pg/ml) in serum. Figure shows individual values, mean
and 95% confidence interval: Healthy controls: 8.2 (6.9–9.9), CF without
chronic infection: 11.4 (9.9–12.8), A. xylosoxidans: 10.4 (8.7–12), Bcc: 12.7
(9.6–15.8), P. aeruginosa: 10.8 (8.7–12.9) (pb0.003).
Fig. 5. Level of IL-6 (pg/ml) in serum. Figure shows individual values, mean
and 95% confidence interval: Healthy controls: 9.2 (−4–22.4), CF without
chronic infection: 11.7 (1.6–21.8), A. xylosoxidans: 23.7 (8.1–39.2), Bcc: 17.3
(2.1–32.6), P. aeruginosa: 25.6 (14.1–37.1) (pb0.003).
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patients when compared to non-infected patients and healthy
controls (pb0.003) (Fig. 5). We found no difference in IL-6
when comparing non-infected CF patients to healthy controls.
Concentrations of IFN-γ were higher in chronically infected
patients compared to CF patients without chronic infections
(pb0.04) (Fig. 6). Chronically infected CF patients had con-
centrations similar to healthy controls.
3.4. Exhaled Breath Condensate
No difference in pH between the groups was found (data not
shown). Levels of cytokines in the EBC were very low. All
samples had TNF-α, IL-1β, IL-6 and IL-10 below detection limit
and 14 of 33 samples had IFN-γ below detection limit.
3.5. Sputum levels of cytokines
The A. xylosoxidans group had higher concentrations of
TNF-α compared to the other chronically infected groups
(pb0.03) (Fig. 7). G-CSF, IFN-γ, IL-6, IL-8 and IL-10 were
measurable in sputum, but no difference in concentrations was
found when comparing the 3 groups.Fig. 4. Level of G-CSF (pg/ml) in serum. Figure shows individual values, mean
and 95% confidence interval: Healthy controls: 39 (24–54.1), CF without
chronic infection: 66.5 (38.6–94.3), A. xylosoxidans: 133 (49.8–216.2), Bcc:
60.4 (41.4–79.4), P. aeruginosa: 111.1 (57–165.3) (pb001).3.6. Antimicrobial susceptibility
In theA. xylosoxidans group, 8 of 11 strains were resistant to 3
or more groups of antibiotics. In the Bcc group, 7 of 11 patients
harboured multiresistant strains. In the P. aeruginosa group the
number was 11 of 21 patients (n.s.).
4. Discussion
Our results show significantly enhanced inflammatory pa-
rameters in combination with progressed lung disease in CF
patients with chronic A. xylosoxidans lung infection. The ability
of this microorganism to cause chronic infection or chronic
colonization is known, but it has been difficult to establish the
clinical significance of this infection. Recent studies have
indicated that patients chronically infected with A. xylosoxidans
may have a more rapid decrease in lung function compared to
CF patients without this infection [36] and a higher percentage
of A. xylosoxidans infected CF patients has been observed
among CF patients awaiting lung transplantation compared to
the general CF community (Brown et al., abstract 359, NACFC
2008). Furthermore, patients with a rapid increase in specific,Fig. 6. IFN-γ (pg/ml) in serum. Figure shows individual values, mean and 95%
confidence interval: Healthy controls: 83.6 (14.5–152.8), CF without chronic
infections: 34.7 (6–63.4), A. xylosoxidans: 34.4 (11.1–57.7), Bcc: 102.3 (−9.3–
213.9), P. aeruginosa: 86.8 (7.2–166.4) (pb0.04).
Fig. 7. Level of TNF-α (pg/ml) in sputum. Figure shows individual values, mean
and 95% confidence interval: A. xylosoxidans: 248.3 (158.1–338.5), Bcc: 129.4
(−8.2–267), P. aeruginosa: 145.8 (14.4–277.2) (pb0.03).
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decline in lung function [36].
It has been suggested that acquisition of chronic A.
xylosoxidans infection is associated to a poor pulmonary status
measured by level of FEV1, % of predicted, at time of estab-
lishment of chronic infection [37]. In the present study, patients
with chronic A. xylosoxidans had levels of FEV1 similar to
controls without chronic infection at time of establishment of
chronic infection. We found that although patients chronically
infected with A. xylosoxidans were younger compared to the
other groups of chronically infected patients and with duration
of chronic infection shorter than the P. aeruginosa group, the
decline in FEV1 was as high as in the P. aeruginosa group,
although lower than in the Bcc group.
Biofilms are consortia of bacteria grown in clusters
surrounded by a self produced polymer matrix (polysacchar-
ides, proteins, DNA). Both A. xylosoxidans and Bcc had
detectable biofilm-like structures in sputum and this was also
the case with mucoid P. aeruginosa as reported previously [42].
The biofilms of A. xylosoxidans and Bcc appeared more dark
and condensed, maybe due to the presence of extracellular DNA
in the biofilm matrix, and this can maybe explain the reduction
of the incidence of such bacteria in sputum of CF patients
treated with nebulized DNase [46]. The presence of biofilms in
sputum from CF patients infected with A. xylosoxidans and Bcc
could explain the unsuccessful eradication of these chronic
infections by antibiotic therapy. Furthermore, similar to chronic
P. aeruginosa infection, the presence of biofilms can worsen the
chronic, probably immune complex-mediated, inflammation
and tissue damage in these patients [42], since the production of
antibodies against biofilm components such as alginate, LPS,
elastase and alkaline protease can lead to formation of immune
complexes [47,48].
Increased inflammation in CF patients is well known and
high levels of cytokines in BAL-fluid have been shown even in
CF infants [7,9,10,14]. Not only in BAL-fluid, but also in
sputum, very high levels of IL-1β, IL-6, IL-8 and TNF-α can be
found in CF patients [7,8,15,43–45,49–53]. These cytokines
increase neutrophilic inflammation in CF airways. Lower than
normal levels of IL-10 have been found in CF epithelial cellsand airway secretions [49,54], leading to inhibited down-
regulation of neutrophilic inflammation. Concentrations of
cytokines in serum are low and have been difficult to measure
[8,43,53], but some correlation to clinical condition has been
found in earlier studies [52,55–57].
The clinical course of the CF lung disease probably depends
on the nature and degree of the inflammatory response. Chronic
P. aeruginosa infection in CF patients is characterized by a Th2
response with higher serum levels of G-CSF and IL-4 [58], and
P. aeruginosa infected CF patients have a higher proportion of
Th2 lymphocytes in BAL-fluid [59]. Th1 response, character-
ized by higher serum levels of IFN-γ and GM-CSF, is dominant
in CF patients with chronic P. aeruginosa infection and milder
disease compared to CF patients with chronic P. aeruginosa
and more severe disease [60,61]. Finally, increasing serum
levels of G-CSF are correlated to decreasing levels of FEV1 in
CF patients with chronic P. aeruginosa infection [57].
In the present study we have shown that patients chronically
infected with A. xylosoxidans had levels of G-CSF in serum
(Fig. 4) comparable to patients with P. aeruginosa and a similar
rate of decline of lung function after development of chronic
infection (Fig. 2). Patients in the Bcc group had lower levels of
G-CSF in serum, yet this group had the fastest decline in lung
function after development of chronic infection. A possible
explanation could be a different inflammatory response in the
Bcc group.
Furthermore we found higher levels of TNF-α in serum from
all CF patients compared to healthy controls. This might be a
result of other, intermittent, infections, such as Staphylococcus
aureus or other microorganisms that all CF patients suffer from
and confirms a report of signs of “background” CF inflamma-
tion found even in newly diagnosed CF infants or maybe shows
the presence of another focus outside the lung, e.g. the paranasal
sinuses [62,63].
IL-6 levels were significantly higher in chronically infected
CF patients when compared to CF patients without chronic,
Gram-negative infections. IL-6 is a pro-inflammatory cytokine
that has not been very extensively studied in CF patients. IL-6
gene expression can be induced by P. aeruginosa infection in a
CF bronchial epithelial cell line [64], and IL-6 levels in BAL-
fluidwere increased in CF childrenwith increasing number of CF
pathogens cultured in BAL-fluid [15]. Finally, IL-6 has been
measured in serum in CF patients chronically infected with P.
aeruginosa. These patients had higher levels of IL-6 compared to
healthy controls [8], and even slightly higher levels than the
levels found in the present study. Our study confirms that
increased concentrations of IL-6 seem to be related to the occur-
rence of infections.
High cytokine concentrations were found in sputum samples
in all chronically infected patients. Concentrations of TNF-α in
sputumwere higher in theA. xylosoxidans group when compared
to other infected groups (Fig. 7). The clinical relevance of the
augmented TNF-α in sputum of the A. xylosoxidans group is
uncertain, but may be particularly important at the site of the
chronic pulmonary infection.
Intrinsic resistance to many antibiotics characterize the A.
xylosoxidans and Bcc strains. We found similar incidences of
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patients but different clinical courses in the groups. A direct
connection between occurrence of multiresistance and a worse
clinical course could not be found in the patients included for
this study.
The inflammatory response in Bcc infected patients appears
to differ from the response found in CF patients chronically
infected with P. aeruginosa. This might partly explain the
different and more aggressive nature of disease related to Bcc
infection and should be further investigated.
5. Conclusion
A. xylosoxidans is a clinically important pathogen in CF
patients causing inflammation and clinical deterioration similar
to the changes found in P. aeruginosa infected CF patients.
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